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Background: This study investigated the long-term effects of humidified high-flow nasal 
cannula (HFNC) in COPD patients with chronic hypoxemic respiratory failure treated with 
long-term oxygen therapy (LTOT).
Patients and methods: A total of 200 patients were randomized into usual care ± HFNC. 
At inclusion, acute exacerbation of COPD (AECOPD) and hospital admissions 1 year before 
inclusion, modified Medical Research Council (mMRC) score, St George’s Respiratory Ques-
tionnaire (SGRQ), forced expiratory volume in 1 second (FEV
1
), 6-minute walk test (6MWT) 
and arterial carbon dioxide (PaCO
2
) were recorded. Patients completed phone interviews at 
1, 3 and 9 months assessing mMRC score and AECOPD since the last contact. At on-site visits 







 and, at 12 months, 6MWT were reassessed. Hospital admissions 
during the study period were obtained from hospital records. Hours of the use of HFNC were 
retrieved from the high-flow device.
Results: The average daily use of HFNC was 6 hours/day. The HFNC group had a lower 
AECOPD rate (3.12 versus 4.95/patient/year, p,0.001). Modeled hospital admission rates were 
0.79 versus 1.39/patient/year for 12- versus 1-month use of HFNC, respectively (p,0.001). The 
HFNC group had improved mMRC scores from 3 months onward (p,0.001) and improved 
SGRQ at 6 and 12 months (p=0.002, p=0.033) and PaCO
2
 (p=0.005) and 6MWT (p=0.005) at 
12 months. There was no difference in all-cause mortality.
Conclusion: HFNC treatment reduced AECOPD, hospital admissions and symptoms in COPD 
patients with hypoxic failure.
Keywords: COPD, high-flow heated and humidified oxygen, HFNC, exacerbation, AECOPD, 
modified Medical Research Council score, mMRC score, 6-minute walk test, 6MWT
Introduction
In advanced COPD, long-term oxygen therapy (LTOT) is an established treatment 
for patients with chronic hypoxemic respiratory failure. LTOT has been shown to 
increase the survival in patients with severe resting hypoxemia, with optimal use 
of $15 hours/day.1,2 The prevalence of LTOT in COPD is 40–48/100,000 patients 
and is increasing.3,4 Adherence to optimal treatment has proved difficult.5 Despite 
improved survival when treated with LTOT, life expectancy is limited when in need of 
LTOT, in part due to concomitant comorbidities and hypercapnic failure,3,6,7 although 
it has been indicated that LTOT stabilizes the partial pressure of arterial carbon 
dioxide (PaCO
2
).8 Moreover, patients are susceptible to acute exacerbation of COPD 
(AECOPD),9 with poor outcomes in terms of mortality and recurrence of AECOPD.10 
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In addition, patients are highly symptomatic,11 have impaired 
quality of life (QoL)12 and limited walking distances, none 
of which improve with LTOT.13
Humidified high-flow nasal cannula (HFNC) with 
optional supplementary oxygen delivery has evolved in 
recent years, with a growing body of evidence of reduced 
respiratory resistance, decreased work load of breathing, 
improved pulmonary compliance, recruitment and mucus 
clearance in adults.14–16 HFNC is primarily established in 
acute and critical care settings for treating mild-to-moderate 
acute hypoxic failure17 and ventilator weaning.18 However, 
there is increasing evidence that HFNC is beneficial in 
chronic respiratory diseases. Recent studies have shown 
increased time to first exacerbation and forced expiratory 
volume in 1 second (FEV
1
) in patients with obstructive lung 
diseases and mucus retention challenges,19 in addition to a 
reduction in respiratory rate,20 PaCO
2
21 and increased exercise 
performance22 in advanced COPD patients and patients with 
chronic hypoxemic respiratory failure. However, knowledge 
about the long-term effect of HFNC is sparse.
Thus, we hypothesize that in COPD patients with chronic 
hypoxemic respiratory failure, long-term HFNC may reduce 
AECOPD rate, dyspnea and mortality as well as increase 
exercise performance. The aim of this study was to inves-
tigate the effects of long-term HFNC in conjunction with 
usual care, including LTOT, with the primary outcome being 
the rate of AECOPD, and, as secondary outcomes, hospital 
admissions; dyspnea, assessed by modified Medical Research 
Council (mMRC) score; QoL, assessed by St George’s Respi-
ratory Questionnaire (SGRQ); PaCO
2
; all-cause mortality 
and exercise performance, measured by 6-minute walk test 
(6MWT).
Patients and methods
In this randomized, prospective trial a total of 200 patients 
were included from 4 outpatient clinics in the North Jutland 
Region of Denmark between December 2013 and July 2015 
(Figure 1). Inclusion criteria were COPD with chronic hypox-
emic respiratory failure (ie, 3 arterial blood gases [ABGs] 
during stable conditions demonstrating hypoxemia)23 and 
previously prescribed LTOT by a pulmonary medicine spe-
cialist, at least 3 months prior to the start of the study. Exclu-
sion criteria were malignant disease, terminal nonmalignant 
disease, unstable psychiatric disease and home treatment 
with noninvasive ventilation (NIV). A change in smoking 
habits during the study period would lead to exclusion. All 
patients received personalized inhaled medicine according 
to Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guidelines,24 had previously undergone pulmonary 
rehabilitation and were in specialized care in connection with 
LTOT treatment, according to the GOLD recommendations.25 
Change of medication and attending rehabilitation were 
allowed, if recommended by the patients’ usual caregivers.
Inclusion
By the use of numbered sealed envelopes containing group 
allocations, patients were randomly assigned to either LTOT 
(controls) or LTOT plus HFNC home treatment delivered by 
Airvo™ via Optiflow™ nasal cannula (both; Fisher & Paykel 
Healthcare, Auckland, New Zealand). A recommended 
20 L/min flow rate was decided upon after an unpublished 
pilot test determined that this was comfortable and allowed 
high compliance during sleep. Starting at 15 L, flow was 
titrated over 30 minutes at the baseline visit. Patients were 
instructed in use of the device, received a written quick 
guide to the device and were recommended to use HFNC 
for 8 hours/day, preferably at night; however, there were no 
restrictions in the duration of use nor time of day.
At inclusion, age, sex, body mass index (BMI), smoking 
status including pack-years, number of AECOPD events 
during the previous year, months treated with LTOT prior 
to inclusion and administered LTOT (L/min) flow was 
recorded. Dyspnea was evaluated by mMRC score, and QoL 
was assessed using SGRQ.
Spirometry was performed (Spida spirometry PC 
software/MicroMedical SpiroUSB™; CareFusion, San 
Diego, CA, USA) according to the American Thoracic and 
European Respiratory Societies’ criteria.26 FEV
1
, forced vital 
capacity (FVC) in the percentage of expected value and the 
FEV
1
/FVC ratio were recorded.
ABG analysis was performed in all patients during 
the administration of usual supplementary oxygen27 (ABL 
800 Flex blood gas analyzer; Radiometer, Copenhagen, 
Denmark). pH, PaCO
2
, partial pressure of oxygen (PaO
2
) 
and arterial oxygen saturation (SaO
2
) were recorded. The 
supplementary oxygen flow rate was kept unaltered during 
HFNC treatment unless SaO
2
,88% was detected. Hyper-
capnic failure was defined as PaCO
2
.6.0 kPa.
A 6MWT was performed,28 with patients using usual 
oxygen flows and use of walkers if needed. Initial oxygen-
pulsed saturation (SpO
2
), heart rate (HR, beats/min) as well 
as minimum SpO
2
 and maximal HR, walking distance and 
BORG score at the end of 6MWT were recorded.
Both the HFNC and control groups received medical care 
by their usual health care providers during the study period, 
including treatment for AECOPD. Patients were instructed 
to keep diary cards for registration of number of AECOPD 
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Long-term high-flow oxygen treatment in COPD
The usual providers of LTOT homecare for both the 
treatment and control groups, AGA, Linde Healthcare, 
Dronninglund, Denmark, delivered and serviced the HFNC 
system during regular home visits. Re-instruction in use of 
the device was given by the technical staff at home delivery 
of HFNC. All patients used the HFNC device with oxygen-
enriched air.
Follow-up
Follow-up is shown in Figure 1. During the 1-year trial 
period, 2 Aalborg University Hospital study nurses conducted 
phone interviews at 1, 3 and 9 months and in-clinic visits at 
6 and 12 months for both HFNC-treated patients and controls. 
Study nurses did not perform home visits.
AECOPD was defined as worsening of symptoms (worsen-
ing of dyspnea, cough and sputum production) for .2 consec-
utive days leading to treatment with systemic glucocorticoids 
or antibiotics.25 Diary cards for AECOPD were read at each 
contact. If in doubt, patients were instructed to consult the 
study nurse in addition to scheduled phone interviews, where 
all registered AECOPDs on diary cards were recorded in the 
study file. In conjunction, the number of hospital admissions 
(at least 24-hour inpatient contact) due to AECOPD (primary 
diagnosis of COPD [ICD-10: DJ44], or a combination of either 
acute respiratory failure [DJ96] or pneumonia [DJ13-18] with 
COPD as a secondary diagnosis) was evaluated at the end of 
the study period from patients’ hospital case records.
mMRC score and smoking status were evaluated at 
each contact.
Lung function and BMI were measured, and SGRQ was 
evaluated at 6- and 12-month visits.
ABGs were drawn while patients were on usual LTOT at 












Figure 1 enrollment, inclusion, follow-up and discontinuation of HFnC-treated patients and controls.
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in patients who were allocated to treatment, ABG analysis 
was repeated. The need to change oxygen levels during the 
use of HFNC was evaluated at each visit.
The 6MWT was repeated at 12 months with recording 
of BORG score and HR.
In the HFNC group, patients reported their daily hours 
of HFNC therapy and diurnal pattern of use at each contact. 
In conjunction, the technical staff read operating hours from 
the HFNC device every second month and the average use 
(hours/day since the last reading) was calculated.
ethics
The study was approved by the North Jutland Ethical Com-
mittee (N-20110057), the Danish Data Protection Agency 
(2008-58-0028), and registered at ClinicalTrials.gov (NCT 
02731872). All patients were informed according to the 
Declaration of Helsinki, and written informed consent was 
obtained prior to inclusion in the study.
Statistical analysis
Sample sizing was based on AECOPD rate being reduced 
by 20% from an historical estimate of 3.80/patient/year. 
Group size of 93 gives 80% power with a 2-sided 5% 
level of significance, which was increased to 100 to be 
conservative. Patients were encouraged to remain in the 
study for assessments even if HFNC was no longer used 
(Figure 1).
The analysis population was defined as all subjects 
randomized to treatment and who had no major protocol 
deviations affecting efficacy data, giving 100% inclusion 
of all 200 subjects enrolled. As such, data were included on 
patients who discontinued the study or paused treatment and 
those who discontinued HFNC but stayed in the study, in the 
HFNC group (intention-to-treat).
Background and pretreatment information is provided 
as mean and SD.
Normally distributed data were analyzed in the gen-
eral linear model framework with the simplest model of 
treatment group augmented by covariates of age and sex 
and, where available, baseline value of the dependent vari-
able. Poisson regression modeling of both AECOPD and 
hospital admissions per patient was completed with the 
length of time in the study used to give estimated rates per 
year per treatment group with the same explanatory model 
as mentioned earlier. Analyses using the 2 groups as ran-
domized are akin to intention to treat. The extra analyses 
where the 2 groups of treatment were replaced by 1 con-
tinuous explanatory variable of actual days of the use of 
HFNC are akin to per protocol. Fitted values from modeling 




Baseline information of the study population is reported 
in Table 1.
HFNC-treated patients and controls were comparable 
at baseline, apart from mMRC score, where HFNC-treated 
patients had a higher mMRC score. Concomitant hypercapnic 
failure was seen in 60% of controls and 52% of HFNC-treated 
patients. Average days in the study were 309 days for HFNC-
treated patients, comparable to controls at 311 days. Mean 
oxygen flow during LTOT remained unaltered at 12 months 
in both groups (1.6 L/min in the HFNC group and 1.7 L/min 
in the control group).
HFnC
Overall, on average, HFNC was used for 248 days, 6 hours/day, 
throughout the study period (readings from the HFNC 
device). Within the first month, 14% of HFNC-treated 
patients stopped using the device, including 3% who left the 
study entirely. The remaining 86% used HFNC for 286 days, 
7 hours/day on average, throughout the study period. HFNC 
was used at night by 53% of the patients; during the day by 
32% and both at night and day by 15%. Patients using HFNC 
at night, or both night and day, used the device significantly 
longer than those using only during daytime (p,0.003). 
By the end of study, 33% of the HFNC group had left the 
study, compared to 29% of the control group (Figure 1). 
Reasons for leaving the study or discontinuing HFNC are 
shown in Figure 1.
No adverse or serious adverse events were recorded.
exacerbations and hospital admissions
AECOPD rates were significantly lower in the HFNC group 
than the control group, 3.12 versus 4.95/patient/year, 
p,0.001 (Figure 2A).
A reduction in AECOPD is also seen with increasing use 
of HFNC (p,0.001), using the actual number of days of the 
use of HFNC as an explanatory continuous variate (eg, zero 
for the control group; Figure 2B). This predicts an AECOPD 
rate of 4.78/patient/year for zero use and 2.89/patient/year 
for 1 year of use for the average patient with 3 AECOPDs 
in the previous year.
There was no significant group difference in hospital 
admission rates (placebo: 1.22/patient/year, HFNC: 1.08/
patient/year, p=0.373; Figure 2C). However,using the 
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Long-term high-flow oxygen treatment in COPD
continuous variate (eg, zero for the control group; Figure 2D), 
a reduction in hospital admissions was seen (using previous 
year admissions as baseline covariate), which predicts an 
admission rate of 1.39/year for zero use and 0.79/year for 
1 year of use for the average patient with 1 admission in the 
previous year (p.0.001). 
Figure 3 shows, in a fitted model, how the study year 
exacerbation rates relate to the previous year’s exacerbations, 
p,0.001, by the treatment group.
mMrC score
Fitted change in mMRC score for HFNC-treated patients and 
controls over the 12-month period is shown in Figure 4A. 
At 3 months, HFNC-treated patients had improved mMRC 
scores (p,0.05), and from 3 months onward they had lower 
mMRC scores compared to controls (p,0.001).
Qol
Changes in SGRQ total score are shown in Figure 4B. HFNC-
treated patients were stable, while controls had a clinically 
significant deterioration of 4.38 over 12 months. As such, 
HFNC-treated patients had better SGRQ at both 6 ( p=0.002) 
and 12 months (p=0.033) compared to controls.
PaCO2
Fitted means for PaCO
2
 are plotted in Figure 4C. Over 
12 months, PaCO
2
 for HFNC-treated patients decreased 
while it increased for controls, resulting in a significant dif-
ference between groups at 12 months (p=0.005). At baseline, 
a 0.29 kPa reduction in PaCO
2
 was seen after 30 minutes of 
HFNC treatment. Similar reductions were seen at 6 (0.28 kPa) 
and 12 months (0.26 kPa).
6MWT
Fitted means for 6MWT are shown in Figure 4D with 
a significant difference at 12 months, p=0.005, exclud-
ing non-walkers. No differences were seen in Borg 
score or HR.
lung function, oxygen levels and BMI
A tendency toward increased FEV
1
% in HFNC-treated 
patients at 6 and 12 months was seen relative to controls 
(p=0.084 and p=0.056, respectively).
A minority of HFNC-treated patients required LTOT oxy-
gen flow rates to be increased. At baseline, this was 15 patients 
(1.0±0.5 L/min), at 6 months 11 patients (1.2±1.0 L/min) and 
Table 1 Background information on the randomized study population, humidified HFNC-treated patients and controls at baseline






Sex, % female 56 63 nS
age, years 71.0 (8.2) 70.4 (9.0) nS
Treated with lTOT prior to inclusion, months 28.9 (32.6) 33.5 (30.6) nS
BMI, kg/m2 25.0 (6.4) 25.4 (6.0) nS
Smoking status, n, never/present/former 1/14/85 0/26/74 nS
Pack-years 41.7 (17.8) 40.5 (19.5) nS
mMrC score 3.3 (0.9) 2.9 (0.9) 0.008
exacerbations in the preceding year 3.23 (3.1) 2.9 (2.8) nS
Current oxygen flow, L 1.6 (0.7) 1.6 (0.8) nS
pH 7.41 (0.04) 7.41 (0.02) nS
PaCO2, kPa 6.5 (1.3) 6.4 (1.0) nS
PaO2, kPa* 9.9 (1.8) 9.9 (1.7) nS
SaO2 95 (3.1) 95 (2.7) nS
FeV1% 29.8 (12.6) 31.8 (12.9) nS
FVC% 64.1 (18.2) 63.9 (19.0) nS
FeV1/FVC 37.5 (11.1) 40.2 (10.3) nS
6MWT (n), m (91) 254.6 (89.2) (96) 245.2 (85.0) nS
Borg score, end of test 6.3 (2.3) 6.2 (2.3) nS
HFNC flow, L 20 (1.1)
Oxygen supply with HFnC, l 1.75 (0.8)
pH after 30 minutes of HFnC 7.42 (0.03)
PaCO2 after 30 minutes of HFnC, kPa 6.2 (1.2)
PaO2 after 30 minutes of HFnC, kPa 8.9 (1.2)
SaO2 after 30 minutes of HFnC, kPa 94 (2.6)
Notes: results are presented as mean (SD) unless otherwise stated. *aBG on usual supplementary oxygen supply.
Abbreviations: aBG, arterial blood gas; BMI, body mass index; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HFNC, high-flow nasal cannula; 
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at 12 months 9 patients (1.2±1.1 L/min). The decrease in the 
number of patients requiring increased oxygen flow on HFNC 
was mainly due to dropout.
There were no significant differences in baseline-adjusted 







the groups at 6 or 12 months. A significant increase in BMI 
in HFNC-treated patients compared to controls was seen at 
6 months (25.7 versus 25.3, respectively, p=0.04). However, 
this was no longer present at 12 months.
Mortality
There was no difference in all-cause mortality between 
treatment groups; 15% for HFNC-treated patients and 12% 
for controls (p=0.636; Figure 1). In the HFNC group, 4 out 
Figure 2 Fitted exacerbation rates (combined reported exacerbations and hospitalized exacerbations) (A, B) and hospital admission rates (C, D).
Notes: In (A and C), blue (control) and red (HFnC) bars show rates per group as randomized (intention-to-treat analysis). In (B and D), the regression line for exacerbations 
(B) and admissions (D) relates actual device use, zero for the control group and 12 months for the study completers, with withdrawal subjects ranging in between (per-
protocol analysis) to the number of events per patient, showing longer actual use giving lower rates of exacerbation and admission.
Abbreviation: HFNC, high-flow nasal cannula.
Figure 3 Fitted values, based on number of exacerbations in the year prior to 
study, of the expected number of exacerbations with zero use (blue dashed) and the 
HFnC-treated (red solid).
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Long-term high-flow oxygen treatment in COPD
of 15 patients discontinued treatment prior to and not in 
connection to death. No association was found between all-
cause mortality and exacerbations.
Discussion
This is the first study reporting on 12 months of treatment 
of LTOT-treated COPD patients using HFNC in a home 
setting.
In this study, for COPD patients who were prescribed 
LTOT, consistent use of HFNC significantly reduced 
AECOPD and hospitalization. Furthermore, HFNC sig-
nificantly reduced mMRC score and preserved SGRQ and 
6MWD, while the control group measures deteriorated. 
A reduction in PaCO
2
 was seen in HFNC-treated patients 
with significant differences in PaCO
2
 levels at 12 months 
compared to controls. Finally, no significant difference was 
seen in all-cause mortality between the 2 groups.
The significant reduction in AECOPD in HFNC-treated 
patients compared to controls is in agreement with a previous 
study by Rea et al,19 where HFNC significantly increased time 
to first exacerbation. However, Rea et al’s study differs in 2 
important ways from this study. First, the study population; 
Rea et al’s study included a mixed population of patients 
with obstructive lung diseases with better lung function and 
few with hypoxic failure compared to those included in this 
study. AECOPD is known to be the strongest predictor for 
future exacerbations,29,30 and patients with chronic hypoxemic 
respiratory failure are known to be even more susceptible to 
AECOPD than normoxic patients,29,31 consistent with the con-
trol group in this study where the number of AECOPD events 
increases over time. However, HFNC significantly reduced the 
risk of AECOPD, with the risk reducing with increasing with 
HFNC treatment time. In our opinion, this strongly supports 
the preventive effect of HFNC treatment on exacerbations, 
Figure 4 Fitted data on mMrC score (A), SGrQ (B), arterial partial pressure of CO2 (C) and 6MWT (D), in high-flow, humidified, nasal cannula delivered oxygen (HFNC) 
patients (red solid line) or controls (blue dashed lines) during the study.
Notes: Dots represent assessment times. p-values show differences between the HFnC and control groups.
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even in very severe COPD patients. HFNC may therefore 
prove to be a novel and an effective non-pharmacological 
treatment adjunct for this group of very severely ill patients.
Second, in Rea et al’s study, HFNC was only used 
1–2 hours/day, compared to the current study with an average 
use of 6–7 hours/day. While Rea et al’s study did not find a 
significant reduction in exacerbations, this study did. This 
indicates that the duration of the use of HFNC is important 
for the reduction in AECOPD. However, this needs further 
scientific substantiation.
In this study, mMRC score improved significantly 
throughout the study period in HFNC-treated patients in 
contrast to controls, where a deterioration was observed. Even 
when following recommended medical treatment, dyspnea 
is one of the most common symptoms of severe COPD 
with a large impact on patient lives.32,33 The most effective 
treatment of dyspnea is rehabilitation,34 yet adherence is 
difficult in more severely ill patients.35 In a recent Cochrane 
review, the effect of oxygen treatment on dyspnea proved to 
be modest.36 The observed effect of HFNC on symptoms is 
therefore notable and substantiates the role of HFNC treat-
ment in COPD chronic care.
This study provides a rare and thorough description of 
the development in clinical features and patho-physiological 
findings in advanced COPD patients with hypoxic failure. 
Despite the control group receiving the recommended treat-
ment for this patient group, they still experienced increased 
hypercapnia, decreased lung function, walking distance 
and QoL. This is consistent with previous findings and is 
associated with poor prognosis.37 This study demonstrates 
that the long-term HFNC treatment decelerates disease 
progression, as seen with 6MWD, QoL and PaCO
2
. The 
significant difference in PaCO
2
 between the HFNC-treated 
and controls after 12 months is consistent with a recent 
study by Nagata et al,38 despite only half the patients being 
hypercapnic at inclusion. In comparison, in a recent meta-
analysis on nocturnal NIV, an alternative add-on treatment 
for severe COPD patients with hypercapnic failure, there 
were no significant differences between the treatment and 
control groups in 6MWD, QoL or PaCO
2
 after 12 months 
of treatment.39 This suggests that HFNC may be superior 
to NIV in slowing disease progression, although further 
investigation is required to substantiate this. The physiologic 
mechanism behind these improvements is as follows: as a 
flow of 20 L/min provides a positive expiratory pressure 
(PEP) of less than 2 cm H
2
O,17 the PEP effect is possibly of 
lesser importance. Despite providing open circuit ventilation, 
HFNC has been shown to increase inspiratory tidal volume 
in COPD, especially when used during daytime use,40,41 
whereas nighttime use has been shown to relieve respira-
tory load.41 Clearance of anatomical dead space is prob-
ably important for the reduction in PaCO
2
.42 However, the 
most important effect in COPD chronic care is most likely 
improved mucociliary clearance, driven by the humidifica-
tion of the air delivered by high flow to distal airways.17 This 
may enhance recruitment, improve alveolar ventilation and 
reduce patients’ respiratory workload. All these mechanisms 
together would decrease the patients’ sensation of dyspnea 
and thereby increase physical ability and, as previously 
indicated, reduce exacerbations.19,43 As such, this study sug-
gests that HFNC should be a treatment used in conjunction 
with LTOT in COPD patients with hypoxic failure to reduce 
exacerbations and maintain health status in general.
The daily duration of the use of HFNC increased when 
patients included nighttime use. Recommended flow was 
based only on the experience of patients’ tolerability; there-
fore, further investigation is needed. However, based on 
this study, we recommend that the use should preferably be 
during sleep, with a flow of at least 20 L/min.
This study has some limitations. A randomized blinded 
study could have been wished for, however, blinding the 
patients against the flow, the heat and the humidity is not realis-
tic. Data on active hours of use of LTOT may have been interest-
ing; however, oxygen delivery device actual use is not currently 
available, and patients’ self-report usage is inaccurate.
Recall bias is possible for AECOPD, and patients’ 
activities, such as rehabilitation, could influence results if 
not evenly distributed within the 2 groups. Differences in 
prescribed medicine and participation in rehabilitation could 
also potentially influence results. However, as patients were 
randomly allocated to the HFNC and control groups, were 
all treated according to guidelines, including referral to vac-
cination and rehabilitation according to national guidelines44 
and received the same standard of care and visits from the 
LTOT homecare company, we expect this to be similar 
between the 2 groups.
The recommendation of 8 hours of the use of HFNC has 
no real scientific background. The only previous long-term 
study recommended 2 hours of use per day, resulting in 
1.6 hours of use on average. Studies on LTOT compliance 
have showed that mobility is important to obtain compliance, 
and this study shows that daytime users use HNFC signifi-
cantly less than nighttime users. An average use of HFNC in 
patients including nighttime use close to the recommended 
8 hours does tell us that this is applicable. However, further 
studies are needed to decide the duration of optimal use. 
Furthermore, this study allowed both day- and nighttime 
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have previously been suggested to be different at day- and 
nighttime, however, this study was performed in healthy 
individuals and the population therefore not necessarily 
comparable to our study population.41 A comparison of the 
effect of day- and nighttime use would be ideal, but was not 
performed in this study as differences in duration of use also 
occur between day- and nighttime use.
One-seventh of the HFNC group ceased treatment within 
the first month, although only 3% left the study population 
completely, while 44% of the study population discontinued 
the use of HFNC during the observation period. However, 
more than one-quarter of those who discontinued died during 
the study. This is substantial, but consistent with prospective 
studies of NIV on comparable patient populations with similar 
treatment durations in the home.45,46 There is of course a risk 
that those who were non-adherent were patients who did not 
feel any physical amelioration, or even felt worse, using HFNC. 
However, as results from the treatment group also included 
those who discontinued use of HFNC but stayed in study and 
as overall study time was similar between the treatment groups 
and controls this is not a likely explanation. Retention rates on 
this study were similar, but by definition, patients remained 
in the control arm longer than in the HFNC arm. Therefore, 
group comparisons were as randomized and more in line with 
an intent-to-treat paradigm. The analyses of exacerbations and 
admissions using actual days of the use of HFNC (eg, zero for 
the control group) were closer to a per-protocol paradigm.
The choice of included variables is always contentious. 
As such, the use of other established symptom scores, eg, 
the COPD assessment test, could have substantiated and 
elaborated description of patients’ symptoms. In addition, the 
clinical relevance of some of the changes, ie, PaCO
2
, is argu-
able. The changes did not lead to significant changes of pH; 
perhaps patients were able to compensate. However, PaCO
2
 
levels have previously been shown to affect the outcome of 
AECOPD in patients with chronic hypoxemic respiratory 
failure,47 even when the PaCO
2
 values were lower than those 
demonstrated in this study. Therefore, the reduction in PaCO
2
 
could have clinical benefit.
Conclusion
This study shows that in COPD with hypoxic failure treated 
with LTOT, adjunct HFNC therapy reduces exacerbations, 
admissions and symptoms. In addition, HFNC stabilizes 
the clinical condition of advanced COPD patients, but does 
not improve all-cause mortality. In future, HFNC should 
therefore be considered a beneficial adjunct to the recom-
mended treatment of COPD patients with chronic hypoxemic 
respiratory failure.
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